<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cardiovasc Disord</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cardiovasc Disord</journal-id><journal-title-group><journal-title>BMC Cardiovascular Disorders</journal-title></journal-title-group><issn pub-type="epub">1471-2261</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26197999</article-id><article-id pub-id-type="pmc">4511433</article-id><article-id pub-id-type="publisher-id">70</article-id><article-id pub-id-type="doi">10.1186/s12872-015-0070-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Specific inhibition of bile acid transport alters plasma lipids and GLP-1</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Rudling</surname><given-names>Mats</given-names></name><address><phone>+46739 660 818</phone><email>mats.rudling@ki.se</email></address><xref ref-type="aff" rid="Aff1"></xref><xref ref-type="aff" rid="Aff2"></xref><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Camilleri</surname><given-names>Michael</given-names></name><address><email>camilleri.michael@mayo.edu</email></address><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Graffner</surname><given-names>Hans</given-names></name><address><email>Hans.Graffner@albireopharma.com</email></address><xref ref-type="aff" rid="Aff5"></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Holst</surname><given-names>Jens Juul</given-names></name><address><email>jjholst@sund.ku.dk</email></address><xref ref-type="aff" rid="Aff6"></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rikner</surname><given-names>Leif</given-names></name><address><email>Leif.Rikner@albireopharma.com</email></address><xref ref-type="aff" rid="Aff5"></xref></contrib><aff id="Aff1"><label></label>Department of Endocrinology, Metabolism and Diabetes, Metabolism Unit, Center for Endocrinology, Metabolism, and Diabetes, Karolinska Institute at Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden </aff><aff id="Aff2"><label></label>Department of Medicine, and Molecular Nutrition Unit, Karolinska Institute at Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden </aff><aff id="Aff3"><label></label>Department of Biosciences and Nutrition, Karolinska Institute at Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden </aff><aff id="Aff4"><label></label>Mayo Clinic, Rochester, MN USA </aff><aff id="Aff5"><label></label>Albireo, Göteborg, Sweden </aff><aff id="Aff6"><label></label>NNF Center for Basic Metabolic Research, the Panum Institute, University of Copenhagen, Copenhagen, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>75</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>14</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>© Rudling et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="4545" xml_f="4555" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4566" xml_f="5217" txt_i="22" txt_f="673">Elobixibat is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor in development against chronic constipation (CC) and constipation-predominant Irritable Bowel Syndrome (IBS-C). CC is associated with an increased risk for cardiovascular disease and type2 diabetes mellitus. The objectives of this study were to evaluate metabolic effects of elobixibat. Effects on plasma lipids and BA synthesis were evaluated utilizing a 4-week, placebo-controlled study in patients with dyslipidemia while changes of glucagon-like peptide-1 (GLP-1) by elobixibat was assayed in samples from a 14 day high-dose elobixibat study in patients with CC.</offsets></p></sec><sec><title><offsets xml_i="5239" xml_f="5246" txt_i="675" txt_f="682">Methods</offsets></title><p><offsets xml_i="5257" xml_f="5773" txt_i="683" txt_f="1199">Thirty-six dyslipidemic patients, 21 females, mean age 63 years, were randomized to 2.5 mg or 5 mg elobixibat or placebo once daily for four weeks. The primary endpoint was the change in low density lipoprotein (LDL) cholesterol. Secondary endpoints included other lipid parameters and serum 7α-hydroxy-4-cholesten-3-one (C4), a marker of BA (bile acid) synthesis. Another study, in 36 patients with CC treated with high dose elobixibat; 15 mg or 20 mg/day or placebo for 14 days, was evaluated for changes in GLP-1.</offsets></p></sec><sec><title><offsets xml_i="5795" xml_f="5802" txt_i="1201" txt_f="1208">Results</offsets></title><p><offsets xml_i="5813" xml_f="5877" txt_i="1209" txt_f="1273">In the dyslipidemia study LDL cholesterol was reduced by 7.4 % (</offsets><italic><offsets xml_i="5885" xml_f="5886" txt_i="1273" txt_f="1274">p</offsets></italic><offsets xml_i="5895" xml_f="5951" txt_i="1274" txt_f="1330"> = 0.044), and the LDL/HDL ratio was decreased by 18 % (</offsets><italic><offsets xml_i="5959" xml_f="5960" txt_i="1330" txt_f="1331">p</offsets></italic><offsets xml_i="5969" xml_f="6168" txt_i="1331" txt_f="1530"> = 0.004). Serum C4 increased, indicating that BA synthesis was induced. No serious adverse events were recorded. In the CC study, GLP-1 increased significantly in both the 15 mg (20.7 ± 2.4 pmol/L; </offsets><italic><offsets xml_i="6176" xml_f="6177" txt_i="1530" txt_f="1531">p</offsets></italic><offsets xml_i="6186" xml_f="6235" txt_i="1531" txt_f="1580"> = 0.03) and the 20 mg group (25.6 ± 4.9 pmol/L; </offsets><italic><offsets xml_i="6243" xml_f="6244" txt_i="1580" txt_f="1581">p</offsets></italic><offsets xml_i="6253" xml_f="6262" txt_i="1581" txt_f="1590"> = 0.02).</offsets></p></sec><sec><title><offsets xml_i="6284" xml_f="6295" txt_i="1592" txt_f="1603">Conclusions</offsets></title><p><offsets xml_i="6306" xml_f="6480" txt_i="1604" txt_f="1778">Elobixibat reduces LDL cholesterol and LDL/HDL ratio and increase circulating peak GLP-1 levels, the latter in line with increased intestinal BA mediated responses in humans.</offsets></p></sec><sec><title><offsets xml_i="6502" xml_f="6521" txt_i="1780" txt_f="1799">Trial registrations</offsets></title><p><offsets xml_i="6532" xml_f="6551" txt_i="1800" txt_f="1819">ClinicalTrial.gov: </offsets><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01069783"><offsets xml_i="6636" xml_f="6647" txt_i="1819" txt_f="1830">NCT01069783</offsets></ext-link><offsets xml_i="6658" xml_f="6663" txt_i="1830" txt_f="1835"> and </offsets><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01038687"><offsets xml_i="6748" xml_f="6759" txt_i="1835" txt_f="1846">NCT01038687</offsets></ext-link><offsets xml_i="6770" xml_f="6771" txt_i="1846" txt_f="1847">.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dyslipidemia</kwd><kwd>Elobixibat</kwd><kwd>Glucagon-like peptide-1 (GLP-1)</kwd><kwd>Ileal bile acid (BA) transporter (IBAT) inhibitor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="7208" xml_f="7218" txt_i="1856" txt_f="1866">Background</offsets></title><p><offsets xml_i="7229" xml_f="7633" txt_i="1867" txt_f="2271">A key step in bile acid (BA) homeostasis is the active uptake of BAs through the apical enterocyte membranes of the distal ileum by the ileal apical sodium-dependent bile acid transporter (IBAT or ASBT [apical sodium-dependent BA transporter]). Inhibition of IBAT reduces the active ileal absorption of BAs, increasing the content of BAs in the colon, thereby stimulating colonic secretion and motility [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="7665" xml_f="7666" txt_i="2271" txt_f="2272">1</offsets></xref><offsets xml_i="7673" xml_f="7675" txt_i="2272" txt_f="2274">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="7707" xml_f="7708" txt_i="2274" txt_f="2275">2</offsets></xref><offsets xml_i="7715" xml_f="7833" txt_i="2275" txt_f="2393">]. Studies of one such inhibitor (elobixibat, previously A3309), have proven beneficial in chronic constipation (CC) [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="7865" xml_f="7866" txt_i="2393" txt_f="2394">3</offsets></xref><offsets xml_i="7873" xml_f="7874" txt_i="2394" txt_f="2395">–</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="7906" xml_f="7907" txt_i="2395" txt_f="2396">5</offsets></xref><offsets xml_i="7914" xml_f="8153" txt_i="2396" txt_f="2635">]. In addition to their role as detergents facilitating dietary lipid absorption, BAs modulate various metabolic events after binding to specific BA receptors such as the farnesoid x receptor (FXR) and the G-protein-coupled receptor TGR5 [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="8185" xml_f="8186" txt_i="2635" txt_f="2636">6</offsets></xref><offsets xml_i="8193" xml_f="8195" txt_i="2636" txt_f="2638">, </offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="8227" xml_f="8228" txt_i="2638" txt_f="2639">7</offsets></xref><offsets xml_i="8235" xml_f="8317" txt_i="2639" txt_f="2721">]. Thus, BAs regulate glucose and lipid metabolism as well as energy expenditure [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="8349" xml_f="8350" txt_i="2721" txt_f="2722">6</offsets></xref><offsets xml_i="8357" xml_f="8359" txt_i="2722" txt_f="2724">].</offsets></p><p><offsets xml_i="8366" xml_f="8670" txt_i="2725" txt_f="3029">When ileal BA absorption decreases, fecal loss of BAs increases resulting in an upregulation of hepatic BA synthesis to maintain BA homeostasis. BA synthesis can be monitored from the level of C4 (7α-hydroxy-4-cholesten-3-one) in serum, a marker for the enzymatic activity of cholesterol 7α-hydroxylase [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="8702" xml_f="8703" txt_i="3029" txt_f="3030">8</offsets></xref><offsets xml_i="8710" xml_f="9320" txt_i="3030" txt_f="3640">], the rate-limiting enzyme in BA synthesis. Cholesterol is precursor in the synthesis of BAs. Induction of BA synthesis depletes hepatic cholesterol stores, which is compensated for through increased hepatic synthesis of cholesterol in combination with an increased number of hepatic low density lipoprotein (LDL) receptors that subsequently reduce plasma LDL cholesterol levels. How BAs modulate glucose homeostasis has lately gained renewed interest with studies claiming increased release of glucagon-like peptide-1 (GLP-1) from the intestine following administration with a bile acid binding sequestrant [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="9352" xml_f="9353" txt_i="3640" txt_f="3641">9</offsets></xref><offsets xml_i="9360" xml_f="9411" txt_i="3641" txt_f="3692">] and after rectal administration of taurocholate [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="9444" xml_f="9446" txt_i="3692" txt_f="3694">10</offsets></xref><offsets xml_i="9453" xml_f="9589" txt_i="3694" txt_f="3830">]. Also the mode of action of the hypoglycemic agent metformin has been suggested to include decreased intestinal bile acid absorption [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9622" xml_f="9624" txt_i="3830" txt_f="3832">11</offsets></xref><offsets xml_i="9631" xml_f="9632" txt_i="3832" txt_f="3833">–</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="9665" xml_f="9667" txt_i="3833" txt_f="3835">13</offsets></xref><offsets xml_i="9674" xml_f="9676" txt_i="3835" txt_f="3837">].</offsets></p><p><offsets xml_i="9683" xml_f="9841" txt_i="3838" txt_f="3996">Elobixibat is a selective and partial inhibitor of IBAT with a novel and unique mechanism of action. After oral administration, systemic exposure is minimal [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="9874" xml_f="9876" txt_i="3996" txt_f="3998">14</offsets></xref><offsets xml_i="9883" xml_f="9924" txt_i="3998" txt_f="4039">]. In three studies in patients with CC [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="9956" xml_f="9957" txt_i="4039" txt_f="4040">3</offsets></xref><offsets xml_i="9964" xml_f="9965" txt_i="4040" txt_f="4041">–</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="9997" xml_f="9998" txt_i="4041" txt_f="4042">5</offsets></xref><offsets xml_i="10005" xml_f="10173" txt_i="4042" txt_f="4210">], elobixibat enhanced colonic transit, thereby improving symptoms of CC such as increased stool frequency concomitant with reduced straining, bloating and hard stools.</offsets></p><p><offsets xml_i="10180" xml_f="10579" txt_i="4211" txt_f="4610">The aim of the present investigation was to evaluate metabolic responses of elobixibat. For this purpose, the level of BA synthesis and serum lipid profiles were monitored in dyslipidemic patients treated with elobixibat for 28 days. In addition, we also evaluated whether such treatment may increase serum levels of the incretin GLP-1 in a study of CC patients treated with elobixibat at high dose.</offsets></p></sec><sec id="Sec2" sec-type="methods"><title><offsets xml_i="10630" xml_f="10637" txt_i="4612" txt_f="4619">Methods</offsets></title><sec id="Sec3"><title><offsets xml_i="10667" xml_f="10689" txt_i="4620" txt_f="4642">The Dyslipidemia study</offsets></title><sec id="Sec4"><title><offsets xml_i="10719" xml_f="10783" txt_i="4643" txt_f="4707">Study design, baseline eligibility, randomization and medication</offsets></title><p><offsets xml_i="10794" xml_f="11254" txt_i="4708" txt_f="5165">This was a single-center, randomized, parallel-group, double-blind, placebo-controlled, two dose, pharmacodynamic study evaluating the effects of elobixibat in dyslipidemic patients. Dyslipidemia was defined as having serum total cholesterol levels &gt;5.5 mmol/L (213 mg/dL). The study was approved by the Linköping University Regional Ethics Review Board. It was performed from February 2010 (first signed informed consent) to July 2010 (last patient visit).</offsets></p><p><offsets xml_i="11261" xml_f="12339" txt_i="5166" txt_f="6244">After informed consent was obtained, patients entered a 14 day screening period when routine blood tests, urinalysis, and pregnancy tests were made and demographic data collected. If screening assessments provided proof of eligibility, the patient was randomized. Patients were randomized to receive one tablet daily containing 2.5 mg elobixibat, 5 mg elobixibat or matching placebo for 28 consecutive days. A randomization list was generated by an independent statistician prior to the study and the assignments were concealed from all study personal until the study was closed and the final data transmitted to the study statistician for analysis. All clinical and laboratory study personnel were blinded throughout the study until data were locked and analyzed. Safety was monitored throughout the study. At Day 14 of the treatment period, a visit to document health status, adverse events (AEs) and for blood sampling took place and at the end of the treatment period a similar visit was scheduled. Fourteen days after last day of treatment, a follow-up visit was conducted.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="12371" xml_f="12387" txt_i="6246" txt_f="6262">Study medication</offsets></title><p><offsets xml_i="12398" xml_f="12655" txt_i="6263" txt_f="6520">The IBAT Inhibitor elobixibat is a small molecule known to be a partial inhibitor of the ileal BA transporter (IBAT). The effects of elobixibat on GI motility and fecal output show an increase in fecal output identified at the lowest dose (1 mg/kg) tested [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="12688" xml_f="12690" txt_i="6520" txt_f="6522">14</offsets></xref><offsets xml_i="12697" xml_f="12699" txt_i="6522" txt_f="6524">].</offsets></p><p><offsets xml_i="12706" xml_f="13212" txt_i="6525" txt_f="7028">Orally administered elobixibat is minimally absorbed from the GI tract with picomolar levels found in plasma, an expected half-life (t½) in humans of &lt;4 h and no metabolites detectable in human plasma. Given its low bioavailability in plasma, it is expected that its action reflects local inhibition of IBAT. In a multiple ascending dose study (0.1–10 mg), administration of elobixibat was found to be safe and tolerable across the dose levels tested with no serious adverse events or discontinuations [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="13244" xml_f="13245" txt_i="7028" txt_f="7029">4</offsets></xref><offsets xml_i="13252" xml_f="13434" txt_i="7029" txt_f="7211">] and in two Phase II studies in patients with CC, dose levels of 5–10–15–20 mg have been evaluated with beneficial effects on stool frequency, stool consistency and symptoms of CC [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="13466" xml_f="13467" txt_i="7211" txt_f="7212">3</offsets></xref><offsets xml_i="13474" xml_f="13476" txt_i="7212" txt_f="7214">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="13508" xml_f="13509" txt_i="7214" txt_f="7215">5</offsets></xref><offsets xml_i="13516" xml_f="13518" txt_i="7215" txt_f="7217">].</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="13550" xml_f="13568" txt_i="7219" txt_f="7237">Study participants</offsets></title><p><offsets xml_i="13579" xml_f="14017" txt_i="7238" txt_f="7667">Eligible patients were men or non-pregnant women, 18–80 years of age with a serum cholesterol of &gt;5.5 mmol/l. The body mass index ranged 18.5 up to 35. Major exclusion criteria were: Known cardiovascular disease, s-cholesterol &gt; 8.5 mmol/l, s-triglycerides &gt; 4.0 mmol/l, use of drugs known to alter lipids and/or BAs within 12 weeks of screening visit, patients meeting the criteria for diagnosis of IBS-D by Rome III standards [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="14050" xml_f="14052" txt_i="7667" txt_f="7669">15</offsets></xref><offsets xml_i="14059" xml_f="14252" txt_i="7669" txt_f="7859">] or had any IBS associated symptoms and/or reported loose (mushy) or watery stools during the 12 weeks prior to the screening visit; exception being short term (&lt;5 days) of gastroenteritis.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="14284" xml_f="14300" txt_i="7861" txt_f="7877">Outcome measures</offsets></title><p><offsets xml_i="14311" xml_f="14943" txt_i="7878" txt_f="8510">The primary end point of the study was the change in LDL (low density lipoprotein) cholesterol from baseline to day 28 of treatment. Secondary efficacy end points included changes from baseline in total cholesterol, HDL (high density lipoprotein) cholesterol, LDL/HDL ratio and total triglycerides to Day 14 and to Day 28 of treatment and C4 evaluation was used as the pharmacodynamic marker of bile acid metabolism. The safety end points included changes from baseline in the nature, incidence and severity of AEs, clinical laboratory abnormalities and changes over time in these parameters, vital signs, ECG and physical findings.</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="14975" xml_f="14994" txt_i="8512" txt_f="8531">Statistical methods</offsets></title><p><offsets xml_i="15005" xml_f="15422" txt_i="8532" txt_f="8949">An intention to treat (ITT) analysis of all randomized subjects was used as the primary analysis. Patients were randomized in a 1:1:1 ratio to the treatment groups. For the primary end point, the sample size selected yielded a power of 80 % with a least significant difference between treatment groups for LDL cholesterol of 0.4. All efficacy end points were analyzed using the Wilcoxon rank sum test and a two-sided </offsets><italic><offsets xml_i="15430" xml_f="15431" txt_i="8949" txt_f="8950">p</offsets></italic><offsets xml_i="15440" xml_f="15532" txt_i="8950" txt_f="9039">-value of &lt;0.05 was considered significant. No adjustment for multiplicity was performed.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="15564" xml_f="15583" txt_i="9041" txt_f="9060">Laboratory analyses</offsets></title><p><offsets xml_i="15594" xml_f="15911" txt_i="9061" txt_f="9378">Conventional safety laboratory parameters including serum glucose and liver function tests were evaluated in both studies. No difference between the active groups and placebo were identified. Assay of plasma lipoproteins LDL, HDL and total cholesterol and total triglycerides were made using routine clinical methods.</offsets></p><p><offsets xml_i="15918" xml_f="16083" txt_i="9379" txt_f="9544">Samples for fasting serum C4 were taken at approximately 8 am and measurements were conducted using high-performance liquid chromatography, as previously described [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="16115" xml_f="16116" txt_i="9544" txt_f="9545">8</offsets></xref><offsets xml_i="16123" xml_f="16125" txt_i="9545" txt_f="9547">].</offsets></p></sec></sec><sec id="Sec10"><title><offsets xml_i="16164" xml_f="16194" txt_i="9550" txt_f="9580">The chronic constipation study</offsets></title><sec id="Sec11"><title><offsets xml_i="16225" xml_f="16286" txt_i="9581" txt_f="9642">Study design, baseline eligibility, randomization, medication</offsets></title><p><offsets xml_i="16297" xml_f="16448" txt_i="9643" txt_f="9794">The demographics and the results pertaining to efficacy in CC and the safety of elobixibat at high dose levels 15 mg and 20 mg/day have been reported [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="16480" xml_f="16481" txt_i="9794" txt_f="9795">5</offsets></xref><offsets xml_i="16488" xml_f="17561" txt_i="9795" txt_f="10868">]. In brief, 36 female patients with CC were included in a 14 day treatment study to evaluate colonic transit and constipation, 15 mg, 20 mg/day or placebo were administered for 14 days. Serum samples were obtained at baseline, in the morning Day 12 and throughout Day 12 (every 30 min for 2 h and then every hour up to 480 min after drug administration). Patients were administered standardized meals; breakfast immediately after the baseline sample, and a light lunch four hrs after baseline sampling. Total GLP-1 concentrations in plasma were measured by radioimmunoassay after extraction of plasma with 70 % ethanol (vol/vol, final concentration) using antiserum 89390 which has an absolute requirement for the intact amidated carboxy-terminus of GLP-1 7–36 amide and crossreacts fully with GLP-1 9–36 amide, the primary metabolite of dipeptidyl-peptidase −4 mediated degradation. The sum of the two components (total GLP-1 concentration) reflects the rate of secretion of the L-cell. Sensitivity was below 1 pmol/l, and intra-assay coefficient of variation below 5 % [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="17594" xml_f="17596" txt_i="10868" txt_f="10870">16</offsets></xref><offsets xml_i="17603" xml_f="17610" txt_i="10870" txt_f="10877">] (16).</offsets></p><p><offsets xml_i="17617" xml_f="17987" txt_i="10878" txt_f="11248">Results are reported as means ± standard error of the mean (SEM) unless otherwise stated. For the analysis of GLP-1, ANCOVA or ANOVA were used depending on whether response or difference vs baseline were evaluated. Comparisons were made between fasting value at start of treatment to fasting value on Day 12 of treatment and comparison of maximum (peak) value on Day 12 </offsets><italic><offsets xml_i="17995" xml_f="17998" txt_i="11248" txt_f="11251">vs.</offsets></italic><offsets xml_i="18007" xml_f="18412" txt_i="11251" txt_f="11656"> at treatment allocation with fasting value before treatment as covariate. Values of the area under the curve (AUC) of serum GLP-1 concentrations were calculated using the trapezoidal rule to assess the integrated response of GLP-1 over 480 min. Statistical analyses are based on t-test/Wilcoxon as indicated in the Figures. Reporting of the studies conform to CONSORT-revised and the EQUATOR guidelines [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="18445" xml_f="18447" txt_i="11656" txt_f="11658">17</offsets></xref><offsets xml_i="18454" xml_f="18456" txt_i="11658" txt_f="11660">].</offsets></p></sec></sec></sec><sec id="Sec12" sec-type="results"><title><offsets xml_i="18520" xml_f="18527" txt_i="11664" txt_f="11671">Results</offsets></title><sec id="Sec13"><title><offsets xml_i="18558" xml_f="18591" txt_i="11672" txt_f="11705">Results of the dyslipidemia study</offsets></title><sec id="Sec14"><title><offsets xml_i="18622" xml_f="18648" txt_i="11706" txt_f="11732">Patient flow and follow-up</offsets></title><p><offsets xml_i="18659" xml_f="18716" txt_i="11733" txt_f="11790">The study flow and patient demographics is shown in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="18748" xml_f="18749" txt_i="11790" txt_f="11791">1</offsets></xref><offsets xml_i="18756" xml_f="19094" txt_i="11791" txt_f="12129">. Out of 81 screened subjects, 36 patients fulfilled eligibility criteria, entered the study and were randomized to treatment with elobixibat or placebo. All patients completed the study; the ITT and the Safety population include the same patients. At baseline, the demographic parameters were similar between the treatment groups (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="19128" xml_f="19130" txt_i="12129" txt_f="12131">1A</offsets></xref><offsets xml_i="19137" xml_f="19307" txt_i="12131" txt_f="12301">). Patients had a mean age of 63 years (range 34–80) and there was a slight preponderance for women (58 %). Baseline lipid profiles were similar across the groups (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="19341" xml_f="19343" txt_i="12301" txt_f="12303">1A</offsets></xref><offsets xml_i="19350" xml_f="19470" txt_i="12303" txt_f="12423">). No changes in safety laboratory values, including liver enzymes and plasma glucose, were identified during the study.</offsets><fig id="Fig1"><label><offsets xml_i="19492" xml_f="19498" txt_i="12423" txt_f="12429">Fig. 1</offsets></label><caption><p><offsets xml_i="19518" xml_f="19562" txt_i="12429" txt_f="12473">Patient flow chart in the Dyslipidemia study</offsets></p></caption><graphic xlink:href="12872_2015_70_Fig1_HTML" id="MO1"></graphic></fig><table-wrap id="Tab1"><label><offsets xml_i="19676" xml_f="19683" txt_i="12474" txt_f="12481">Table 1</offsets></label><caption><p><offsets xml_i="19703" xml_f="19739" txt_i="12481" txt_f="12517">Demographics and baseline parameters</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5"><offsets xml_i="19817" xml_f="19838" txt_i="12518" txt_f="12539">A. Dyslipidemia study</offsets></th></tr><tr><th colspan="2"></th><th><offsets xml_i="19877" xml_f="19886" txt_i="12539" txt_f="12548">Placebo (</offsets><italic><offsets xml_i="19894" xml_f="19895" txt_i="12548" txt_f="12549">N</offsets></italic><offsets xml_i="19904" xml_f="19910" txt_i="12549" txt_f="12555"> = 12)</offsets></th><th><offsets xml_i="19919" xml_f="19938" txt_i="12555" txt_f="12574">Elobixibat 2.5 mg (</offsets><italic><offsets xml_i="19946" xml_f="19947" txt_i="12574" txt_f="12575">N</offsets></italic><offsets xml_i="19956" xml_f="19962" txt_i="12575" txt_f="12581"> = 12)</offsets></th><th><offsets xml_i="19971" xml_f="19988" txt_i="12581" txt_f="12598">Elobixibat 5 mg (</offsets><italic><offsets xml_i="19996" xml_f="19997" txt_i="12598" txt_f="12599">N</offsets></italic><offsets xml_i="20006" xml_f="20012" txt_i="12599" txt_f="12605"> = 12)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="20045" xml_f="20051" txt_i="12605" txt_f="12611">Female</offsets></td><td><offsets xml_i="20060" xml_f="20065" txt_i="12612" txt_f="12617">n (%)</offsets></td><td><offsets xml_i="20074" xml_f="20082" txt_i="12618" txt_f="12626">8 (66.7)</offsets></td><td><offsets xml_i="20091" xml_f="20099" txt_i="12627" txt_f="12635">7 (58.3)</offsets></td><td><offsets xml_i="20108" xml_f="20116" txt_i="12636" txt_f="12644">6 (50.0)</offsets></td></tr><tr><td><offsets xml_i="20134" xml_f="20143" txt_i="12645" txt_f="12654">Caucasian</offsets></td><td><offsets xml_i="20152" xml_f="20157" txt_i="12655" txt_f="12660">n (%)</offsets></td><td><offsets xml_i="20166" xml_f="20176" txt_i="12661" txt_f="12671">12 (100.0)</offsets></td><td><offsets xml_i="20185" xml_f="20195" txt_i="12672" txt_f="12682">12 (100.0)</offsets></td><td><offsets xml_i="20204" xml_f="20214" txt_i="12683" txt_f="12693">12 (100.0)</offsets></td></tr><tr><td><offsets xml_i="20232" xml_f="20243" txt_i="12694" txt_f="12705">Age (years)</offsets></td><td><offsets xml_i="20252" xml_f="20261" txt_i="12706" txt_f="12715">Mean (SD)</offsets></td><td><offsets xml_i="20270" xml_f="20281" txt_i="12716" txt_f="12727">64.4 (10.1)</offsets></td><td><offsets xml_i="20290" xml_f="20301" txt_i="12728" txt_f="12739">60.9 (13.2)</offsets></td><td><offsets xml_i="20310" xml_f="20321" txt_i="12740" txt_f="12751">62.7 (11.4)</offsets></td></tr><tr><td><offsets xml_i="20339" xml_f="20350" txt_i="12752" txt_f="12763">Weight (kg)</offsets></td><td><offsets xml_i="20359" xml_f="20368" txt_i="12764" txt_f="12773">Mean (SD)</offsets></td><td><offsets xml_i="20377" xml_f="20388" txt_i="12774" txt_f="12785">76.2 (16.3)</offsets></td><td><offsets xml_i="20397" xml_f="20408" txt_i="12786" txt_f="12797">78.1 (16.4)</offsets></td><td><offsets xml_i="20417" xml_f="20428" txt_i="12798" txt_f="12809">76.6 (12.8)</offsets></td></tr><tr><td><offsets xml_i="20446" xml_f="20455" txt_i="12810" txt_f="12819">BMI (kg/m</offsets><sup><offsets xml_i="20460" xml_f="20461" txt_i="12819" txt_f="12820">2</offsets></sup><offsets xml_i="20467" xml_f="20468" txt_i="12820" txt_f="12821">)</offsets></td><td><offsets xml_i="20477" xml_f="20483" txt_i="12822" txt_f="12828">Median</offsets></td><td><offsets xml_i="20492" xml_f="20496" txt_i="12829" txt_f="12833">24.8</offsets></td><td><offsets xml_i="20505" xml_f="20509" txt_i="12834" txt_f="12838">26.3</offsets></td><td><offsets xml_i="20518" xml_f="20522" txt_i="12839" txt_f="12843">26.4</offsets></td></tr><tr><td><offsets xml_i="20540" xml_f="20564" txt_i="12844" txt_f="12868">LDL-Cholesterol (mmol/L)</offsets></td><td><offsets xml_i="20573" xml_f="20582" txt_i="12869" txt_f="12878">Mean (SD)</offsets></td><td><offsets xml_i="20591" xml_f="20602" txt_i="12879" txt_f="12890">4.29 (0.71)</offsets></td><td><offsets xml_i="20611" xml_f="20622" txt_i="12891" txt_f="12902">4.61 (0.63)</offsets></td><td><offsets xml_i="20631" xml_f="20642" txt_i="12903" txt_f="12914">4,78 (0.65)</offsets></td></tr><tr><td><offsets xml_i="20660" xml_f="20680" txt_i="12915" txt_f="12935">Cholesterol (mmol/L)</offsets></td><td><offsets xml_i="20689" xml_f="20698" txt_i="12936" txt_f="12945">Mean (SD)</offsets></td><td><offsets xml_i="20707" xml_f="20718" txt_i="12946" txt_f="12957">6.38 (0.75)</offsets></td><td><offsets xml_i="20727" xml_f="20738" txt_i="12958" txt_f="12969">6.44 (0.57)</offsets></td><td><offsets xml_i="20747" xml_f="20758" txt_i="12970" txt_f="12981">6.57 (0.72)</offsets></td></tr><tr><td><offsets xml_i="20776" xml_f="20800" txt_i="12982" txt_f="13006">HDL-Cholesterol (mmol/L)</offsets></td><td><offsets xml_i="20809" xml_f="20818" txt_i="13007" txt_f="13016">Mean (SD)</offsets></td><td><offsets xml_i="20827" xml_f="20838" txt_i="13017" txt_f="13028">1.53 (0.49)</offsets></td><td><offsets xml_i="20847" xml_f="20858" txt_i="13029" txt_f="13040">1.34 (0.43)</offsets></td><td><offsets xml_i="20867" xml_f="20878" txt_i="13041" txt_f="13052">1.23 (0.30)</offsets></td></tr><tr><td><offsets xml_i="20896" xml_f="20924" txt_i="13053" txt_f="13081">LDL/HDL-Cholesterol (mmol/L)</offsets></td><td><offsets xml_i="20933" xml_f="20942" txt_i="13082" txt_f="13091">Mean (SD)</offsets></td><td><offsets xml_i="20951" xml_f="20962" txt_i="13092" txt_f="13103">3.00 (0.92)</offsets></td><td><offsets xml_i="20971" xml_f="20982" txt_i="13104" txt_f="13115">3.77 (1.60)</offsets></td><td><offsets xml_i="20991" xml_f="21002" txt_i="13116" txt_f="13127">4.32 (1.73)</offsets></td></tr><tr><td colspan="5"><offsets xml_i="21032" xml_f="21047" txt_i="13128" txt_f="13143">B. The CC study</offsets></td></tr><tr><td colspan="2"></td><td><offsets xml_i="21086" xml_f="21095" txt_i="13145" txt_f="13154">Placebo (</offsets><italic><offsets xml_i="21103" xml_f="21104" txt_i="13154" txt_f="13155">N</offsets></italic><offsets xml_i="21113" xml_f="21119" txt_i="13155" txt_f="13161"> = 13)</offsets></td><td><offsets xml_i="21128" xml_f="21146" txt_i="13162" txt_f="13180">Elobixibat 15 mg (</offsets><italic><offsets xml_i="21154" xml_f="21155" txt_i="13180" txt_f="13181">N</offsets></italic><offsets xml_i="21164" xml_f="21170" txt_i="13181" txt_f="13187"> = 12)</offsets></td><td><offsets xml_i="21179" xml_f="21197" txt_i="13188" txt_f="13206">Elobixibat 20 mg (</offsets><italic><offsets xml_i="21205" xml_f="21206" txt_i="13206" txt_f="13207">N</offsets></italic><offsets xml_i="21215" xml_f="21221" txt_i="13207" txt_f="13213"> = 11)</offsets></td></tr><tr><td><offsets xml_i="21239" xml_f="21245" txt_i="13214" txt_f="13220">Female</offsets></td><td><offsets xml_i="21254" xml_f="21259" txt_i="13221" txt_f="13226">n (%)</offsets></td><td><offsets xml_i="21268" xml_f="21278" txt_i="13227" txt_f="13237">13 (100.0)</offsets></td><td><offsets xml_i="21287" xml_f="21297" txt_i="13238" txt_f="13248">12 (100.0)</offsets></td><td><offsets xml_i="21306" xml_f="21316" txt_i="13249" txt_f="13259">11 (100.0)</offsets></td></tr><tr><td><offsets xml_i="21334" xml_f="21343" txt_i="13260" txt_f="13269">Caucasian</offsets></td><td><offsets xml_i="21352" xml_f="21357" txt_i="13270" txt_f="13275">n (%)</offsets></td><td><offsets xml_i="21366" xml_f="21375" txt_i="13276" txt_f="13285">11 (92.3)</offsets></td><td><offsets xml_i="21384" xml_f="21394" txt_i="13286" txt_f="13296">12 (100.0)</offsets></td><td><offsets xml_i="21403" xml_f="21413" txt_i="13297" txt_f="13307">12 (100.0)</offsets></td></tr><tr><td><offsets xml_i="21431" xml_f="21442" txt_i="13308" txt_f="13319">Age (years)</offsets></td><td><offsets xml_i="21451" xml_f="21460" txt_i="13320" txt_f="13329">Mean (SD)</offsets></td><td><offsets xml_i="21469" xml_f="21480" txt_i="13330" txt_f="13341">47.2 (9.30)</offsets></td><td><offsets xml_i="21489" xml_f="21500" txt_i="13342" txt_f="13353">38.3 (8.18)</offsets></td><td><offsets xml_i="21509" xml_f="21520" txt_i="13354" txt_f="13365">46.1 (6.36)</offsets></td></tr><tr><td><offsets xml_i="21538" xml_f="21549" txt_i="13366" txt_f="13377">Weight (kg)</offsets></td><td><offsets xml_i="21558" xml_f="21567" txt_i="13378" txt_f="13387">Mean (SD)</offsets></td><td><offsets xml_i="21576" xml_f="21586" txt_i="13388" txt_f="13398">70.2 (9.7)</offsets></td><td><offsets xml_i="21595" xml_f="21606" txt_i="13399" txt_f="13410">72.9 (15.5)</offsets></td><td><offsets xml_i="21615" xml_f="21626" txt_i="13411" txt_f="13422">75.0 (17.0)</offsets></td></tr><tr><td><offsets xml_i="21644" xml_f="21653" txt_i="13423" txt_f="13432">BMI (kg/m</offsets><sup><offsets xml_i="21658" xml_f="21659" txt_i="13432" txt_f="13433">2</offsets></sup><offsets xml_i="21665" xml_f="21666" txt_i="13433" txt_f="13434">)</offsets></td><td><offsets xml_i="21675" xml_f="21681" txt_i="13435" txt_f="13441">Median</offsets></td><td><offsets xml_i="21690" xml_f="21694" txt_i="13442" txt_f="13446">25.9</offsets></td><td><offsets xml_i="21703" xml_f="21707" txt_i="13447" txt_f="13451">24.8</offsets></td><td><offsets xml_i="21716" xml_f="21720" txt_i="13452" txt_f="13456">26.0</offsets></td></tr><tr><td><offsets xml_i="21738" xml_f="21752" txt_i="13457" txt_f="13471">GLP-1 (pmol/L)</offsets></td><td><offsets xml_i="21761" xml_f="21770" txt_i="13472" txt_f="13481">Mean (SD)</offsets></td><td><offsets xml_i="21779" xml_f="21784" txt_i="13482" txt_f="13487">18.45</offsets><sup><offsets xml_i="21789" xml_f="21790" txt_i="13487" txt_f="13488">a</offsets></sup><offsets xml_i="21796" xml_f="21803" txt_i="13488" txt_f="13495"> (8.63)</offsets></td><td><offsets xml_i="21812" xml_f="21824" txt_i="13496" txt_f="13508">15.08 (5.38)</offsets></td><td><offsets xml_i="21833" xml_f="21838" txt_i="13509" txt_f="13514">14.67</offsets><sup><offsets xml_i="21843" xml_f="21844" txt_i="13514" txt_f="13515">b</offsets></sup><offsets xml_i="21850" xml_f="21857" txt_i="13515" txt_f="13522"> (5.92)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="21903" xml_f="21904" txt_i="13523" txt_f="13524">
</offsets><sup><offsets xml_i="21909" xml_f="21910" txt_i="13524" txt_f="13525">a</offsets></sup><offsets xml_i="21916" xml_f="21917" txt_i="13525" txt_f="13526">
</offsets><italic><offsets xml_i="21925" xml_f="21926" txt_i="13526" txt_f="13527">n</offsets></italic><offsets xml_i="21935" xml_f="21940" txt_i="13527" txt_f="13532"> = 11</offsets></p><p><offsets xml_i="21947" xml_f="21948" txt_i="13533" txt_f="13534">
</offsets><sup><offsets xml_i="21953" xml_f="21954" txt_i="13534" txt_f="13535">b</offsets></sup><offsets xml_i="21960" xml_f="21961" txt_i="13535" txt_f="13536">
</offsets><italic><offsets xml_i="21969" xml_f="21970" txt_i="13536" txt_f="13537">n</offsets></italic><offsets xml_i="21979" xml_f="21983" txt_i="13537" txt_f="13541"> = 9</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title><offsets xml_i="22051" xml_f="22100" txt_i="13544" txt_f="13593">Effects of elobixibat on lipid profiles and on C4</offsets></title><p><offsets xml_i="22111" xml_f="22136" txt_i="13594" txt_f="13619">There was a significant (</offsets><italic><offsets xml_i="22144" xml_f="22145" txt_i="13619" txt_f="13620">p</offsets></italic><offsets xml_i="22154" xml_f="22315" txt_i="13620" txt_f="13781"> = 0.044) change from baseline to end of treatment in LDL cholesterol (7.4 %) for the 5 mg elobixibat treatment group – the primary end point of the study (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="22347" xml_f="22348" txt_i="13781" txt_f="13782">2</offsets></xref><offsets xml_i="22355" xml_f="22683" txt_i="13782" txt_f="14110">). No significant change was achieved for the 2.5 mg elobixibat cohort. When analyzing the mean and median change values from baseline to Days 14 and 28, there was a more prominent reduction in the drug-treated groups as compared to placebo whereas on day 42 (14 days after cessation of treatment) there was no clear difference.</offsets><fig id="Fig2"><label><offsets xml_i="22705" xml_f="22711" txt_i="14110" txt_f="14116">Fig. 2</offsets></label><caption><p><offsets xml_i="22731" xml_f="22899" txt_i="14116" txt_f="14284">Median % changes (interquartile 25–75 % range) from baseline for plasma total cholesterol, LDL, HDL, LDL/HDL ratio and triglycerides (TG) in the Dyslipidemia study. *: </offsets><italic><offsets xml_i="22907" xml_f="22908" txt_i="14284" txt_f="14285">p</offsets></italic><offsets xml_i="22917" xml_f="22930" txt_i="14285" txt_f="14298"> = 0.044 **: </offsets><italic><offsets xml_i="22938" xml_f="22939" txt_i="14298" txt_f="14299">p</offsets></italic><offsets xml_i="22948" xml_f="22967" txt_i="14299" txt_f="14318"> = 0.004 (Wilcoxon)</offsets></p></caption><graphic xlink:href="12872_2015_70_Fig2_HTML" id="MO2"></graphic></fig></p><p><offsets xml_i="23059" xml_f="23166" txt_i="14320" txt_f="14427">Elobixibat treatment did not significantly alter total cholesterol, HDL cholesterol or triglycerides (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="23198" xml_f="23199" txt_i="14427" txt_f="14428">2</offsets></xref><offsets xml_i="23206" xml_f="23295" txt_i="14428" txt_f="14517">). In contrast, the LDL/HDL ratio was significantly reduced on Day 28 in the 5 mg group (</offsets><italic><offsets xml_i="23303" xml_f="23304" txt_i="14517" txt_f="14518">p</offsets></italic><offsets xml_i="23313" xml_f="23394" txt_i="14518" txt_f="14599"> = 0.004) (18 %) whereas no effect was seen in the 2.5 mg group (p = 0.06) (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="23426" xml_f="23427" txt_i="14599" txt_f="14600">2</offsets></xref><offsets xml_i="23434" xml_f="23436" txt_i="14600" txt_f="14602">).</offsets></p><p><offsets xml_i="23443" xml_f="23538" txt_i="14603" txt_f="14698">C4 was significantly increased in both the 2.5 mg and in the 5 mg elobixibat groups on Day 28 (</offsets><italic><offsets xml_i="23546" xml_f="23547" txt_i="14698" txt_f="14699">p</offsets></italic><offsets xml_i="23556" xml_f="23587" txt_i="14699" txt_f="14730"> = 0.03 for both groups) (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="23619" xml_f="23620" txt_i="14730" txt_f="14731">3</offsets></xref><offsets xml_i="23627" xml_f="23629" txt_i="14731" txt_f="14733">).</offsets><fig id="Fig3"><label><offsets xml_i="23651" xml_f="23657" txt_i="14733" txt_f="14739">Fig. 3</offsets></label><caption><p><offsets xml_i="23677" xml_f="23782" txt_i="14739" txt_f="14844">Median % changes (interquartile 25–75 % range) from baseline for plasma C4 in the Dyslipidemia study. *: </offsets><italic><offsets xml_i="23790" xml_f="23791" txt_i="14844" txt_f="14845">p</offsets></italic><offsets xml_i="23800" xml_f="23820" txt_i="14845" txt_f="14862"> &lt;0.03 (Wilcoxon)</offsets></p></caption><graphic xlink:href="12872_2015_70_Fig3_HTML" id="MO3"></graphic></fig></p></sec><sec id="Sec16"><title><offsets xml_i="23938" xml_f="23956" txt_i="14865" txt_f="14883">Safety assessments</offsets></title><p><offsets xml_i="23967" xml_f="24481" txt_i="14884" txt_f="15398">No serious adverse events (SAEs) were reported during the dyslipidemia study. AEs were most prevalent in the placebo group (92 % of the patients reported 27 AEs). In the 2.5 mg and 5 mg treatment groups, 50 % and 67 % of the patients reported a total of 11 and 14 AEs respectively. Most of the AEs were recorded as mild and transient and only four were moderate, two in the placebo group and two in the 5 mg group; none of them were judged to be related to the study drug. No patient discontinued the study. Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="24515" xml_f="24516" txt_i="15398" txt_f="15399">2</offsets></xref><offsets xml_i="24523" xml_f="24718" txt_i="15399" txt_f="15594"> outlines the incidence of AEs. The most common AEs were headache, diarrhea and constipation. Notably, diarrhea was reported in 3 patients on placebo, 2 patients on 2.5 mg and 3 patients on 5 mg.</offsets><table-wrap id="Tab2"><label><offsets xml_i="24747" xml_f="24754" txt_i="15594" txt_f="15601">Table 2</offsets></label><caption><p><offsets xml_i="24774" xml_f="24916" txt_i="15601" txt_f="15743">Adverse events occurring in more than one subject in the Dyslipidemia study. No serious adverse events and no discontinuations were identified</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"></th><th><offsets xml_i="25003" xml_f="25012" txt_i="15744" txt_f="15753">Placebo (</offsets><italic><offsets xml_i="25020" xml_f="25021" txt_i="15753" txt_f="15754">N</offsets></italic><offsets xml_i="25030" xml_f="25036" txt_i="15754" txt_f="15760"> = 12)</offsets></th><th><offsets xml_i="25045" xml_f="25061" txt_i="15760" txt_f="15776">A3309 - 2.5 mg (</offsets><italic><offsets xml_i="25069" xml_f="25070" txt_i="15776" txt_f="15777">N</offsets></italic><offsets xml_i="25079" xml_f="25085" txt_i="15777" txt_f="15783"> = 12)</offsets></th><th><offsets xml_i="25094" xml_f="25108" txt_i="15783" txt_f="15797">A3309 - 5 mg (</offsets><italic><offsets xml_i="25116" xml_f="25117" txt_i="15797" txt_f="15798">N</offsets></italic><offsets xml_i="25126" xml_f="25132" txt_i="15798" txt_f="15804"> = 12)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="25165" xml_f="25190" txt_i="15804" txt_f="15829">MedDRA system organ class</offsets></td><td><offsets xml_i="25199" xml_f="25220" txt_i="15830" txt_f="15851">MedDRA preferred term</offsets></td><td><offsets xml_i="25229" xml_f="25234" txt_i="15852" txt_f="15857">n (%)</offsets></td><td><offsets xml_i="25243" xml_f="25248" txt_i="15858" txt_f="15863">n (%)</offsets></td><td><offsets xml_i="25257" xml_f="25262" txt_i="15864" txt_f="15869">n (%)</offsets></td></tr><tr><td><offsets xml_i="25280" xml_f="25306" txt_i="15870" txt_f="15896">Gastrointestinal disorders</offsets></td><td><offsets xml_i="25315" xml_f="25335" txt_i="15897" txt_f="15917">Abdominal distension</offsets></td><td><offsets xml_i="25344" xml_f="25351" txt_i="15918" txt_f="15925">1 (8.3)</offsets></td><td><offsets xml_i="25360" xml_f="25367" txt_i="15926" txt_f="15933">1 (8.3)</offsets></td><td><offsets xml_i="25376" xml_f="25383" txt_i="15934" txt_f="15941">1 (8.3)</offsets></td></tr><tr><td></td><td><offsets xml_i="25410" xml_f="25422" txt_i="15943" txt_f="15955">Constipation</offsets></td><td><offsets xml_i="25431" xml_f="25439" txt_i="15956" txt_f="15964">4 (33.3)</offsets></td><td><offsets xml_i="25448" xml_f="25455" txt_i="15965" txt_f="15972">1 (8.3)</offsets></td><td><offsets xml_i="25464" xml_f="25465" txt_i="15973" txt_f="15974">-</offsets></td></tr><tr><td></td><td><offsets xml_i="25492" xml_f="25501" txt_i="15976" txt_f="15985">Diarrhoea</offsets></td><td><offsets xml_i="25510" xml_f="25518" txt_i="15986" txt_f="15994">3 (25.0)</offsets></td><td><offsets xml_i="25527" xml_f="25535" txt_i="15995" txt_f="16003">2 (16.7)</offsets></td><td><offsets xml_i="25544" xml_f="25552" txt_i="16004" txt_f="16012">3 (25.0)</offsets></td></tr><tr><td><offsets xml_i="25570" xml_f="25622" txt_i="16013" txt_f="16065">General disorders and administration site conditions</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td><offsets xml_i="25685" xml_f="25692" txt_i="16071" txt_f="16078">Pyrexia</offsets></td><td><offsets xml_i="25701" xml_f="25708" txt_i="16079" txt_f="16086">1 (8.3)</offsets></td><td><offsets xml_i="25717" xml_f="25718" txt_i="16087" txt_f="16088">-</offsets></td><td><offsets xml_i="25727" xml_f="25734" txt_i="16089" txt_f="16096">1 (8.3)</offsets></td></tr><tr><td><offsets xml_i="25752" xml_f="25779" txt_i="16097" txt_f="16124">Infections and infestations</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td><offsets xml_i="25842" xml_f="25853" txt_i="16130" txt_f="16141">Pharyngitis</offsets></td><td><offsets xml_i="25862" xml_f="25869" txt_i="16142" txt_f="16149">1 (8.3)</offsets></td><td><offsets xml_i="25878" xml_f="25879" txt_i="16150" txt_f="16151">-</offsets></td><td><offsets xml_i="25888" xml_f="25895" txt_i="16152" txt_f="16159">1 (8.3)</offsets></td></tr><tr><td></td><td><offsets xml_i="25922" xml_f="25930" txt_i="16161" txt_f="16169">Rhinitis</offsets></td><td><offsets xml_i="25939" xml_f="25947" txt_i="16170" txt_f="16178">2 (16.7)</offsets></td><td><offsets xml_i="25956" xml_f="25957" txt_i="16179" txt_f="16180">-</offsets></td><td><offsets xml_i="25966" xml_f="25967" txt_i="16181" txt_f="16182">-</offsets></td></tr><tr><td><offsets xml_i="25985" xml_f="26032" txt_i="16183" txt_f="16230">Musculoskeletal and connective tissue disorders</offsets></td><td><offsets xml_i="26041" xml_f="26048" txt_i="16231" txt_f="16238">Myalgia</offsets></td><td><offsets xml_i="26057" xml_f="26065" txt_i="16239" txt_f="16247">2 (16.7)</offsets></td><td><offsets xml_i="26074" xml_f="26075" txt_i="16248" txt_f="16249">-</offsets></td><td><offsets xml_i="26084" xml_f="26085" txt_i="16250" txt_f="16251">-</offsets></td></tr><tr><td><offsets xml_i="26103" xml_f="26127" txt_i="16252" txt_f="16276">Nervous system disorders</offsets></td><td><offsets xml_i="26136" xml_f="26145" txt_i="16277" txt_f="16286">Dizziness</offsets></td><td><offsets xml_i="26154" xml_f="26162" txt_i="16287" txt_f="16295">2 (16.7)</offsets></td><td><offsets xml_i="26171" xml_f="26172" txt_i="16296" txt_f="16297">-</offsets></td><td><offsets xml_i="26181" xml_f="26182" txt_i="16298" txt_f="16299">-</offsets></td></tr><tr><td></td><td><offsets xml_i="26209" xml_f="26217" txt_i="16301" txt_f="16309">Headache</offsets></td><td><offsets xml_i="26226" xml_f="26234" txt_i="16310" txt_f="16318">3 (25.0)</offsets></td><td><offsets xml_i="26243" xml_f="26251" txt_i="16319" txt_f="16327">3 (25.0)</offsets></td><td><offsets xml_i="26260" xml_f="26268" txt_i="16328" txt_f="16336">3 (25.0)</offsets></td></tr><tr><td><offsets xml_i="26286" xml_f="26313" txt_i="16337" txt_f="16364">Renal and urinary disorders</offsets></td><td><offsets xml_i="26322" xml_f="26330" txt_i="16365" txt_f="16373">Polyuria</offsets></td><td><offsets xml_i="26339" xml_f="26346" txt_i="16374" txt_f="16381">1 (8.3)</offsets></td><td><offsets xml_i="26355" xml_f="26362" txt_i="16382" txt_f="16389">1 (8.3)</offsets></td><td><offsets xml_i="26371" xml_f="26372" txt_i="16390" txt_f="16391">-</offsets></td></tr><tr><td><offsets xml_i="26390" xml_f="26437" txt_i="16392" txt_f="16439">Respiratory, thoracic and mediastinal disorders</offsets></td><td><offsets xml_i="26446" xml_f="26451" txt_i="16440" txt_f="16445">Cough</offsets></td><td><offsets xml_i="26460" xml_f="26467" txt_i="16446" txt_f="16453">1 (8.3)</offsets></td><td><offsets xml_i="26476" xml_f="26477" txt_i="16454" txt_f="16455">-</offsets></td><td><offsets xml_i="26486" xml_f="26493" txt_i="16456" txt_f="16463">1 (8.3)</offsets></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec17"><title><offsets xml_i="26571" xml_f="26594" txt_i="16467" txt_f="16490">Results of the CC study</offsets></title><p><offsets xml_i="26605" xml_f="26651" txt_i="16491" txt_f="16537">Demographic parameters are described in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="26685" xml_f="26687" txt_i="16537" txt_f="16539">1B</offsets></xref><offsets xml_i="26694" xml_f="26808" txt_i="16539" txt_f="16653">. Efficacy on pharmacodynamics and clinical endpoints of CC and safety assessments have been reported previously [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="26840" xml_f="26841" txt_i="16653" txt_f="16654">5</offsets></xref><offsets xml_i="26848" xml_f="26850" txt_i="16654" txt_f="16656">].</offsets></p><p><offsets xml_i="26857" xml_f="26974" txt_i="16657" txt_f="16774">No changes in safety laboratory values, including liver enzymes and plasma glucose, were identified during the study.</offsets></p><sec id="Sec18"><title><offsets xml_i="27001" xml_f="27074" txt_i="16775" txt_f="16848">Effects of elobixibat on circulating GLP-1 levels in constipated patients</offsets></title><p><offsets xml_i="27085" xml_f="27270" txt_i="16849" txt_f="17034">Peak values for GLP-1 levels increased significantly during the day, when adjusted for baseline values, for both the 15 mg (20.7 ± 2.4 pmol/L) and the 20 mg (25.6 ± 4.9 pmol/L) groups (</offsets><italic><offsets xml_i="27278" xml_f="27279" txt_i="17034" txt_f="17035">p</offsets></italic><offsets xml_i="27288" xml_f="27300" txt_i="17035" txt_f="17047"> = 0.03 and </offsets><italic><offsets xml_i="27308" xml_f="27309" txt_i="17047" txt_f="17048">p</offsets></italic><offsets xml_i="27318" xml_f="27388" txt_i="17048" txt_f="17118"> = 0.02 respectively) compared with placebo (12.8 ± 2.4 pmol/L) (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="27420" xml_f="27421" txt_i="17118" txt_f="17119">4</offsets></xref><offsets xml_i="27428" xml_f="27793" txt_i="17119" txt_f="17484">). Peak values were observed at lunch time. No significant differences were observed for the basal morning levels at Day 12 of treatment when compared to levels prior to treatment. Similarly, there were no significant differences in total AUC levels during the 480 min period (201 ± 12 pmol/L*hr (15 mg), 225 ± 27 pmol/L*hr (20 mg) and 180 ± 27 pmol/L*hr (placebo).</offsets><fig id="Fig4"><label><offsets xml_i="27815" xml_f="27821" txt_i="17484" txt_f="17490">Fig. 4</offsets></label><caption><p><offsets xml_i="27841" xml_f="27976" txt_i="17490" txt_f="17625">GLP-1 (pmol/L) in the CC study. Data shown are the difference between peak values Day 12 and the basal pre-study value. Mean ± SEM. *: </offsets><italic><offsets xml_i="27984" xml_f="27985" txt_i="17625" txt_f="17626">p</offsets></italic><offsets xml_i="27994" xml_f="28015" txt_i="17626" txt_f="17644"> &lt; 0.05 (Wilcoxon)</offsets></p></caption><graphic xlink:href="12872_2015_70_Fig4_HTML" id="MO4"></graphic></fig></p></sec></sec></sec><sec id="Sec19" sec-type="discussion"><title><offsets xml_i="28167" xml_f="28177" txt_i="17649" txt_f="17659">Discussion</offsets></title><p><offsets xml_i="28188" xml_f="28649" txt_i="17660" txt_f="18121">The current results provide insight in metabolic responses obtained when administering an IBAT inhibitor to dyslipidemic patients with elevated cholesterol levels, and when employed at high dose to patients with CC. At a dose of 5 mg elobixibat reduced LDL cholesterol by 7.4 % and decreased the LDL/HDL ratio by 18 %. The reduced LDL/HDL ratio is of particular interest since it is an important risk factor for the development of cardiovascular disease (CVD) [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="28682" xml_f="28684" txt_i="18121" txt_f="18123">18</offsets></xref><offsets xml_i="28691" xml_f="28789" txt_i="18123" txt_f="18221">]. The beneficial effects of elobixibat on serum lipids confirm previous findings by Chey et al. [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="28821" xml_f="28822" txt_i="18221" txt_f="18222">3</offsets></xref><offsets xml_i="28829" xml_f="29235" txt_i="18222" txt_f="18628">]. A limitation of this paper is the fact that data have been collected from two different populations (patients with dyslipidemia or with chronic constipation). It would have been of interest to assess GLP-1 in patients with dyslipidemia as well and to perform a thorough analysis of subfractions of LDL and HDL but given the set-up of the study, this was not possible due to restrictions in the sampling.</offsets></p><p><offsets xml_i="29242" xml_f="29344" txt_i="18629" txt_f="18731">Although no patient discontinued the study, signs of increased colonic transit were identified (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="29378" xml_f="29379" txt_i="18731" txt_f="18732">2</offsets></xref><offsets xml_i="29386" xml_f="29562" txt_i="18732" txt_f="18908">). On the other hand, the improved LDL/HDL ratio should be beneficial in patients with CC. This because it has been reported that constipation is a risk factor for CVD events [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="29595" xml_f="29597" txt_i="18908" txt_f="18910">19</offsets></xref><offsets xml_i="29604" xml_f="29930" txt_i="18910" txt_f="19236">] as shown from women with severe constipation having a 23 % higher risk for CVD events, and an unadjusted risk of death due to CVD almost five-fold higher: 3.25 (95 % CI 1.76–5.01) in severe constipation as compared to 0.76 (95 % CI 0.54–1.06)/1000 person-years in subjects without constipation. Moreover, Salmoirago et al. [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="29963" xml_f="29965" txt_i="19236" txt_f="19238">19</offsets></xref><offsets xml_i="29972" xml_f="30198" txt_i="19238" txt_f="19464">] reported that the more severe state of constipation at baseline, the more frequent is the use of cholesterol-lowering medication. Further support for a relation between atherosclerosis and constipation was found in a study [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="30231" xml_f="30233" txt_i="19464" txt_f="19466">20</offsets></xref><offsets xml_i="30240" xml_f="30452" txt_i="19466" txt_f="19678">] on patients with known CVD having a 2.5-fold higher prevalence of constipation as compared to subjects without constipation. Cholesterol is to a great extent eliminated from the body through fecal loss of BAs [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="30485" xml_f="30487" txt_i="19678" txt_f="19680">21</offsets></xref><offsets xml_i="30494" xml_f="30546" txt_i="19680" txt_f="19732">] (21) that is clearly reduced in patients with CC [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="30579" xml_f="30581" txt_i="19732" txt_f="19734">22</offsets></xref><offsets xml_i="30588" xml_f="30589" txt_i="19734" txt_f="19735">–</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="30622" xml_f="30624" txt_i="19735" txt_f="19737">24</offsets></xref><offsets xml_i="30631" xml_f="30755" txt_i="19737" txt_f="19861">]. Interestingly, also in patients with CVD, fecal BA excretion is significantly reduced as compared with non-CVD patients [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="30788" xml_f="30790" txt_i="19861" txt_f="19863">25</offsets></xref><offsets xml_i="30797" xml_f="30799" txt_i="19863" txt_f="19865">].</offsets></p><p><offsets xml_i="30806" xml_f="31119" txt_i="19866" txt_f="20179">Considering the above findings, it is conceivable that an IBAT inhibitor like elobixibat administered for the treatment of CC may be particularly attractive not only to relieve symptoms of constipation but also to lower LDL cholesterol and reduce the increased risk for CVD observed in subjects with constipation.</offsets></p><p><xref ref-type="bibr" rid="CR6"><offsets xml_i="31158" xml_f="31159" txt_i="20180" txt_f="20181">6</offsets></xref><offsets xml_i="31166" xml_f="31168" txt_i="20181" txt_f="20183">, </offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="31200" xml_f="31201" txt_i="20183" txt_f="20184">7</offsets></xref><offsets xml_i="31208" xml_f="31210" txt_i="20184" txt_f="20186">, </offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="31242" xml_f="31243" txt_i="20186" txt_f="20187">9</offsets></xref><offsets xml_i="31250" xml_f="31252" txt_i="20187" txt_f="20189">, </offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="31285" xml_f="31287" txt_i="20189" txt_f="20191">26</offsets></xref><offsets xml_i="31294" xml_f="31296" txt_i="20191" txt_f="20193">, </offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="31329" xml_f="31331" txt_i="20193" txt_f="20195">27</offsets></xref><offsets xml_i="31338" xml_f="31465" txt_i="20195" txt_f="20322">]. As compared to treatment with DPP-4 inhibitors, the meal-induced plasma GLP-1 levels with elobixibat treatment are smaller [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="31498" xml_f="31500" txt_i="20322" txt_f="20324">28</offsets></xref><offsets xml_i="31507" xml_f="31809" txt_i="20324" txt_f="20626">]. However, it is important to point out that the meal stimulus in this study was a standardized low calorie chicken breast lunch, and that GLP-1 AUC measurements were evaluated over a longer time period, most likely inducing a lower response than a high calorie load or an oral glucose tolerance test.</offsets></p><p><offsets xml_i="31816" xml_f="31921" txt_i="20627" txt_f="20732">The most commonly used drug in T2DM, metformin, probably in part acts through enhancing GLP-1 secretion [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="31954" xml_f="31956" txt_i="20732" txt_f="20734">28</offsets></xref><offsets xml_i="31963" xml_f="32092" txt_i="20734" txt_f="20863">]. This effect may be mediated through IBAT inhibition since metformin is known to suppress active BA absorption from the ileum [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="32125" xml_f="32127" txt_i="20863" txt_f="20865">11</offsets></xref><offsets xml_i="32134" xml_f="32168" txt_i="20865" txt_f="20899">]. Although data are not uniform [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="32201" xml_f="32203" txt_i="20899" txt_f="20901">29</offsets></xref><offsets xml_i="32210" xml_f="32294" txt_i="20901" txt_f="20985">] other IBAT-inhibitors have demonstrated incretin-releasing properties in animals [</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="32327" xml_f="32329" txt_i="20985" txt_f="20987">30</offsets></xref><offsets xml_i="32336" xml_f="32481" txt_i="20987" txt_f="21132">]. Intriguingly, BA sequestrants like cholestyramine bind BAs and therefore reduce free BAs in the colon, have been reported beneficial in T2DM [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="32514" xml_f="32516" txt_i="21132" txt_f="21134">31</offsets></xref><offsets xml_i="32523" xml_f="32619" txt_i="21134" txt_f="21230">]. Results have shown that colesevelam when bound to BAs may activate TGR-5 receptors in vitro [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="32652" xml_f="32654" txt_i="21230" txt_f="21232">10</offsets></xref><offsets xml_i="32661" xml_f="32828" txt_i="21232" txt_f="21399">]. On the other hand, in healthy humans cholestyramine-induced changes of serum glucose can appear independent of serum GLP-1 levels (Rudling M, unpublished research).</offsets></p><p><offsets xml_i="32835" xml_f="33042" txt_i="21400" txt_f="21607">The positive effects of IBAT-inhibition on GLP-1 secretion may thus be particularly beneficial in CC patients with T2DM or pre-diabetes; two disease entities associated with increased risk for constipation [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="33075" xml_f="33077" txt_i="21607" txt_f="21609">18</offsets></xref><offsets xml_i="33084" xml_f="33086" txt_i="21609" txt_f="21611">, </offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="33119" xml_f="33121" txt_i="21611" txt_f="21613">32</offsets></xref><offsets xml_i="33128" xml_f="33130" txt_i="21613" txt_f="21615">, </offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="33163" xml_f="33165" txt_i="21615" txt_f="21617">33</offsets></xref><offsets xml_i="33172" xml_f="33174" txt_i="21617" txt_f="21619">].</offsets></p></sec><sec id="Sec20" sec-type="conclusions"><title><offsets xml_i="33230" xml_f="33240" txt_i="21621" txt_f="21631">Conclusion</offsets></title><p><offsets xml_i="33251" xml_f="34009" txt_i="21632" txt_f="22390">In summary, the studies reported here provide evidence of decreased LDL cholesterol and increased GLP-1 levels when using elobixibat in patients with dyslipidemia and with CC respectively; these effects are consistent with metabolic effects of BAs in the ileocolonic region in humans. Further development of IBAT-inhibitors to combat metabolic disease will possibly be restricted by the effects of IBAT inhibition on colonic transit, resulting in diarrhea. However, given the association between symptoms of constipation with cardiovascular disease and T2DM, it seems that an IBAT inhibitor like elobixibat, in addition to positive effects on symptoms and signs of constipation, may provide positive metabolic side effects reducing the risk for CVD and T2DM.</offsets></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ASBT</term><def><p>Apical sodium-dependent BA transporter</p></def></def-item><def-item><term>BA</term><def><p>Bile acids</p></def></def-item><def-item><term>C4</term><def><p>7α-hydroxy-4-cholesten-3-one</p></def></def-item><def-item><term>CC</term><def><p>Chronic constipation</p></def></def-item><def-item><term>FXR</term><def><p>Farnesoid X receptor</p></def></def-item><def-item><term>GLP-1</term><def><p>Glucagonlike peptide 1</p></def></def-item><def-item><term>HDL</term><def><p>High density lipoprotein</p></def></def-item><def-item><term>IBAT</term><def><p>Ileal bile acid transporter</p></def></def-item><def-item><term>IBS-C</term><def><p>Constipation-predominant irritable bowel syndrome</p></def></def-item><def-item><term>HDL</term><def><p>High density lipoprotein</p></def></def-item><def-item><term>T2DM</term><def><p>Type2 diabetes mellitus</p></def></def-item></def-list></glossary><fn-group><fn><p>Mats Rudling, Michael Camilleri, Hans Graffner, Jens Juul Holst and Leif Rikner contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>Dr. Rudling has received a scientific grant from Albireo.</p><p>Dr. Camilleri serves as a member of an advisory board of Albireo with compensation to his employer, Mayo Clinic only and not to him. Dr. Graffner and Mr. Rikner are employees of Albireo, Goteborg, Sweden.</p></fn><fn><p><bold>Authors’ contributions</bold></p><p>MR: Principal investigator in the dyslipidemia study, study design, data analysis and interpretation, writing protocol and paper. MC: Principal investigator in the CC study, study conception and design, data analysis and interpretation, writing protocol and paper. HG: Study conception and design, data analysis and interpretation, writing protocol and paper. JJH: Analysis of GLP-1, data analysis and interpretation, writing paper. LR: Study conception and design, data analysis and interpretation, writing protocol and paper. All author read and approved the final manuscript.</p></fn></fn-group><ack><p>The studies were supported by grants from Albireo.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bampton</surname><given-names>PA</given-names></name><name><surname>Dinning</surname><given-names>PG</given-names></name><name><surname>Kennedy</surname><given-names>ML</given-names></name><name><surname>Lubowski</surname><given-names>DZ</given-names></name><name><surname>Cook</surname><given-names>IJ</given-names></name></person-group><article-title>The proximal colonic motor response to rectal mechanical and chemical stimulation</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2002</year><volume>282</volume><fpage>G443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00194.2001</pub-id><pub-id pub-id-type="pmid">11841994</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekjian</surname><given-names>HS</given-names></name><name><surname>Phillips</surname><given-names>SF</given-names></name><name><surname>Hofmann</surname><given-names>AF</given-names></name></person-group><article-title>Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man</article-title><source>J Clin Invest</source><year>1971</year><volume>50</volume><fpage>1569</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1172/JCI106644</pub-id><pub-id pub-id-type="pmid">4938344</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Rikner</surname><given-names>L</given-names></name><name><surname>Graffner</surname><given-names>H</given-names></name></person-group><article-title>A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation</article-title><source>Am J Gastroenterol</source><year>2011</year><volume>106</volume><fpage>1803</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1038/ajg.2011.162</pub-id><pub-id pub-id-type="pmid">21606974</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simren</surname><given-names>M</given-names></name><name><surname>Bajor</surname><given-names>A</given-names></name><name><surname>Gillberg</surname><given-names>PG</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name><name><surname>Abrahamsson</surname><given-names>H</given-names></name></person-group><article-title>Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>34</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2011.04675.x</pub-id><pub-id pub-id-type="pmid">21545606</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>BS</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>McKinzie</surname><given-names>S</given-names></name><name><surname>Burton</surname><given-names>D</given-names></name><name><surname>Graffner</surname><given-names>H</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name></person-group><article-title>Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation</article-title><source>Am J Gastroenterol</source><year>2011</year><volume>106</volume><fpage>2154</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1038/ajg.2011.285</pub-id><pub-id pub-id-type="pmid">21876564</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pols</surname><given-names>TW</given-names></name><name><surname>Noriega</surname><given-names>LG</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Schoonjans</surname><given-names>K</given-names></name></person-group><article-title>The bile acid membrane receptor TGR5: a valuable metabolic target</article-title><source>Dig Dis</source><year>2011</year><volume>29</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1159/000324126</pub-id><pub-id pub-id-type="pmid">21691102</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Gioiello</surname><given-names>A</given-names></name><name><surname>Noriega</surname><given-names>L</given-names></name><name><surname>Strehle</surname><given-names>A</given-names></name><name><surname>Oury</surname><given-names>J</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Macchiarulo</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Mataki</surname><given-names>C</given-names></name><name><surname>Pruzanski</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>TGR5-mediated bile acid sensing controls glucose homeostasis</article-title><source>Cell Metab</source><year>2009</year><volume>10</volume><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.08.001</pub-id><pub-id pub-id-type="pmid">19723493</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galman</surname><given-names>C</given-names></name><name><surname>Arvidsson</surname><given-names>I</given-names></name><name><surname>Angelin</surname><given-names>B</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name></person-group><article-title>Monitoring hepatic cholesterol 7{alpha}-hydroxylase activity by assay of the stable bile acid intermediate 7{alpha}-hydroxy-4-cholesten-3-one in peripheral blood</article-title><source>J Lipid Res</source><year>2003</year><volume>44</volume><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1194/jlr.D200043-JLR200</pub-id><pub-id pub-id-type="pmid">12562858</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuma</surname><given-names>S</given-names></name><name><surname>Hirasawa</surname><given-names>A</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name></person-group><article-title>Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>329</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.01.139</pub-id><pub-id pub-id-type="pmid">15721318</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potthoff</surname><given-names>MJ</given-names></name><name><surname>Potts</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Duarte</surname><given-names>JA</given-names></name><name><surname>Taussig</surname><given-names>R</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Burgess</surname><given-names>SC</given-names></name></person-group><article-title>Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2013</year><volume>304</volume><fpage>G371</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00400.2012</pub-id><pub-id pub-id-type="pmid">23257920</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>D</given-names></name><name><surname>Howlett</surname><given-names>HC</given-names></name><name><surname>Wiernsperger</surname><given-names>NF</given-names></name><name><surname>Bailey</surname><given-names>CJ</given-names></name></person-group><article-title>Differential effects of metformin on bile salt absorption from the jejunum and ileum</article-title><source>Diabetes Obes Metab</source><year>2003</year><volume>5</volume><fpage>120</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1046/j.1463-1326.2003.00252.x</pub-id><pub-id pub-id-type="pmid">12630937</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caspary</surname><given-names>WF</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group><article-title>Inhibition of bile salt absorption by blood-sugar lowering biguanides</article-title><source>Diabetologia</source><year>1975</year><volume>11</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/BF00429833</pub-id><pub-id pub-id-type="pmid">1149945</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarpello</surname><given-names>JH</given-names></name><name><surname>Hodgson</surname><given-names>E</given-names></name><name><surname>Howlett</surname><given-names>HC</given-names></name></person-group><article-title>Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus</article-title><source>Diabet Med</source><year>1998</year><volume>15</volume><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9136(199808)15:8&lt;651::AID-DIA628&gt;3.0.CO;2-A</pub-id><pub-id pub-id-type="pmid">9702467</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillberg</surname><given-names>PG</given-names></name><name><surname>Dahlström</surname><given-names>M</given-names></name><name><surname>Starke</surname><given-names>I</given-names></name><name><surname>Ostlund-Lindquist</surname><given-names>A-M</given-names></name></person-group><article-title>The IBAT inhibition by A3309 - A potential mechanism for the treatment of constipation</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>S</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(10)61017-7</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longstreth</surname><given-names>GF</given-names></name><name><surname>Thompson</surname><given-names>WG</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Houghton</surname><given-names>LA</given-names></name><name><surname>Mearin</surname><given-names>F</given-names></name><name><surname>Spiller</surname><given-names>RC</given-names></name></person-group><article-title>Functional bowel disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1480</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.11.061</pub-id><pub-id pub-id-type="pmid">16678561</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Rabenhoj</surname><given-names>L</given-names></name><name><surname>Wettergren</surname><given-names>A</given-names></name><name><surname>Kofod</surname><given-names>H</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans</article-title><source>Diabetes</source><year>1994</year><volume>43</volume><fpage>535</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.2337/diab.43.4.535</pub-id><pub-id pub-id-type="pmid">8138058</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simera</surname><given-names>I</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Hoey</surname><given-names>J</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>A catalogue of reporting guidelines for health research</article-title><source>Eur J Clin Invest</source><year>2010</year><volume>40</volume><fpage>35</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2009.02234.x</pub-id><pub-id pub-id-type="pmid">20055895</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Sipahi</surname><given-names>I</given-names></name><name><surname>Grasso</surname><given-names>AW</given-names></name><name><surname>Schoenhagen</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><name><surname>Crowe</surname><given-names>T</given-names></name><name><surname>Desai</surname><given-names>MY</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name><etal></etal></person-group><article-title>Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis</article-title><source>JAMA</source><year>2007</year><volume>297</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1001/jama.297.5.499</pub-id><pub-id pub-id-type="pmid">17284700</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmoirago-Blotcher</surname><given-names>E</given-names></name><name><surname>Crawford</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>E</given-names></name><name><surname>Ockene</surname><given-names>J</given-names></name><name><surname>Ockene</surname><given-names>I</given-names></name></person-group><article-title>Constipation and risk of cardiovascular disease among postmenopausal women</article-title><source>Am J Med</source><year>2011</year><volume>124</volume><fpage>714</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2011.03.026</pub-id><pub-id pub-id-type="pmid">21663887</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shakir</surname><given-names>YA</given-names></name><name><surname>Samsioe</surname><given-names>G</given-names></name><name><surname>Khatibi</surname><given-names>EA</given-names></name><name><surname>Nyberg</surname><given-names>P</given-names></name><name><surname>Lidfeldt</surname><given-names>J</given-names></name><name><surname>Agardh</surname><given-names>CD</given-names></name><name><surname>Nerbrand</surname><given-names>C</given-names></name></person-group><article-title>Health hazards in middle-aged women with cardiovascular disease: a case–control study of swedish women. the women’s health in the Lund area (WHILA) study</article-title><source>J Womens Health (Larchmt)</source><year>2007</year><volume>16</volume><fpage>406</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1089/jwh.2006.0056</pub-id><pub-id pub-id-type="pmid">17439385</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelin</surname><given-names>B</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name></person-group><article-title>Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era?</article-title><source>Curr Opin Lipid</source><year>1999</year><volume>10</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1097/00041433-199906000-00009</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahamsson</surname><given-names>H</given-names></name><name><surname>Ostlund-Lindqvist</surname><given-names>AM</given-names></name><name><surname>Nilsson</surname><given-names>R</given-names></name><name><surname>Simren</surname><given-names>M</given-names></name><name><surname>Gillberg</surname><given-names>PG</given-names></name></person-group><article-title>Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation</article-title><source>Scand J Gastroenterol</source><year>2008</year><volume>43</volume><fpage>1483</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1080/00365520802321212</pub-id><pub-id pub-id-type="pmid">18788050</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>AF</given-names></name><name><surname>Loening-Baucke</surname><given-names>V</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><name><surname>Hagey</surname><given-names>LR</given-names></name><name><surname>Steinbach</surname><given-names>JH</given-names></name><name><surname>Packard</surname><given-names>CA</given-names></name><name><surname>Griffin</surname><given-names>TL</given-names></name><name><surname>Chatfield</surname><given-names>DA</given-names></name></person-group><article-title>Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2008</year><volume>47</volume><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e31816920a6</pub-id><pub-id pub-id-type="pmid">18955863</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>BS</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>P</given-names></name><name><surname>McKinzie</surname><given-names>S</given-names></name><name><surname>Busciglio</surname><given-names>I</given-names></name><name><surname>Bondar</surname><given-names>O</given-names></name><name><surname>Dyer</surname><given-names>RB</given-names></name><name><surname>Lamsam</surname><given-names>J</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name></person-group><article-title>Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea</article-title><source>Clin Gastroenterol Hepatol</source><year>2012</year><volume>10</volume><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2012.05.006</pub-id><pub-id pub-id-type="pmid">22610000</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charach</surname><given-names>G</given-names></name><name><surname>Grosskopf</surname><given-names>I</given-names></name><name><surname>Rabinovich</surname><given-names>A</given-names></name><name><surname>Shochat</surname><given-names>M</given-names></name><name><surname>Weintraub</surname><given-names>M</given-names></name><name><surname>Rabinovich</surname><given-names>P</given-names></name></person-group><article-title>The association of bile acid excretion and atherosclerotic coronary artery disease</article-title><source>Therap Adv Gastroenterol</source><year>2011</year><volume>4</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1177/1756283X10388682</pub-id><pub-id pub-id-type="pmid">21694811</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harach</surname><given-names>T</given-names></name><name><surname>Pols</surname><given-names>TW</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Maida</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Schoonjans</surname><given-names>K</given-names></name></person-group><article-title>TGR5 potentiates GLP-1 secretion in response to anionic exchange resins</article-title><source>Sci Rep</source><year>2012</year><volume>2</volume><fpage>430</fpage><pub-id pub-id-type="doi">10.1038/srep00430</pub-id><pub-id pub-id-type="pmid">22666533</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knop</surname><given-names>FK</given-names></name></person-group><article-title>Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?</article-title><source>Am J Physiol Endocrinol Metab</source><year>2010</year><volume>299</volume><fpage>E10</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00137.2010</pub-id><pub-id pub-id-type="pmid">20424139</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migoya</surname><given-names>EM</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JL</given-names></name><name><surname>Snyder</surname><given-names>RN</given-names></name><name><surname>Tanen</surname><given-names>M</given-names></name><name><surname>Hilliard</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>B</given-names></name><name><surname>Larson</surname><given-names>P</given-names></name><name><surname>Gutierrez</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>88</volume><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.184</pub-id><pub-id pub-id-type="pmid">21048706</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>Q</given-names></name><name><surname>Saumoy</surname><given-names>M</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Salen</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name></person-group><article-title>Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2010</year><volume>298</volume><fpage>G419</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00362.2009</pub-id><pub-id pub-id-type="pmid">20044510</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>McNulty</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Nystrom</surname><given-names>C</given-names></name><name><surname>Croom</surname><given-names>D</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes</article-title><source>Am J Physiol Endocrinol Metab</source><year>2012</year><volume>302</volume><fpage>E68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00323.2011</pub-id><pub-id pub-id-type="pmid">21934041</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinton</surname><given-names>EA</given-names></name></person-group><article-title>Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation</article-title><source>Diabetes Obes Metab</source><year>2008</year><volume>10</volume><fpage>1004</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2008.00903.x</pub-id><pub-id pub-id-type="pmid">18494807</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bytzer</surname><given-names>P</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Leemon</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>LJ</given-names></name><name><surname>Jones</surname><given-names>MP</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name></person-group><article-title>Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults</article-title><source>Arch Intern Med</source><year>2001</year><volume>161</volume><fpage>1989</fpage><lpage>1996</lpage><pub-id pub-id-type="doi">10.1001/archinte.161.16.1989</pub-id><pub-id pub-id-type="pmid">11525701</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Nuyts</surname><given-names>G</given-names></name><name><surname>Dubois</surname><given-names>D</given-names></name></person-group><article-title>Risk factors for chronic constipation based on a general practice sample</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><fpage>1107</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07465.x</pub-id><pub-id pub-id-type="pmid">12809835</pub-id></element-citation></ref></ref-list></back></article>